373 related articles for article (PubMed ID: 17286767)
1. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
[TBL] [Abstract][Full Text] [Related]
3. The epidemiology of factor VIII inhibitors.
Hay CR
Haemophilia; 2006 Dec; 12 Suppl 6():23-8; discussion 28-9. PubMed ID: 17123390
[TBL] [Abstract][Full Text] [Related]
4. Treatment related factors and inhibitor development in children with severe haemophilia A.
Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
[TBL] [Abstract][Full Text] [Related]
5. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
6. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
7. Risk of inhibitor development in mild haemophilia A increases with age.
Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
10. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
13. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of inhibitors and current treatment strategies.
Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
[TBL] [Abstract][Full Text] [Related]
16. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
17. Assessment of incidence of inhibitors in patients with haemophilia.
van der Bom JG; ter Avest P; Van den Berg HM; Psaty BM; Weiss NS
Haemophilia; 2009 May; 15(3):707-11. PubMed ID: 19432923
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors: our greatest challenge. Can we minimize the incidence?
Kruse-Jarres R
Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.
Lee CA; Lillicrap D; Astermark J
Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():10-4. PubMed ID: 16804830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
